People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Other Technology, Other Health Care, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mangata Networks, Inc. | — | Other Technology | Series B | $61.0M | $363.9M | 2022 |
| Akadeum Life Sciences, Inc. | — | Other Health Care | Series A | $15.4M | $20.5M | 2017 |
| Daintree Networks Inc. | — | Other Technology | Series A | $12.0M | $111.0M | 2010 |
| FibeRio Technology Corp | — | Other Technology | Seed | $11.3M | $68.9M | 2012 |
| Sylogist USA Inc. | — | Other Technology | Series A | $6.6M | $158.3M | 2020 |
| Boundless Network Inc | — | Other Technology | Seed | $3.0M | $102.2M | 2009 |
| Hive9, Inc. | — | Other Technology | Seed | $2.7M | $92.0M | 2015 |
| Sylogist Ltd | — | Other Technology | Series A | $770K | $18.5M | 2020 |
| Avail Productivity Systems, LLC | — | Software / Tech | Pre-Seed | $140K | $5.9M | 2017 |
William Wood at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Wood on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Xavier Shorter | 2 | 2 |
| David Elder | 2 | 2 |
| Krishna Srinivasan | 1 | 18 |
| Paul Brown | 1 | 12 |
| C. Thomas Ball | 1 | 12 |
| Bruce Leak | 1 | 8 |
| Robert Morris | 1 | 7 |
| Ebetuel Pallares | 1 | 7 |
| Larry Schwartz | 1 | 5 |
| George Dunbar | 1 | 5 |
| Benjamin Brown | 1 | 5 |
| Jory Bell | 1 | 4 |
| Paul D'Amato | 1 | 4 |
| Dan Kidle | 1 | 4 |
| Rosa McCormick | 1 | 4 |
| Doug Martin | 1 | 3 |
| Teresa Engelhard | 1 | 3 |
| Ellery Buchanan | 1 | 3 |
| Brian Holz | 1 | 2 |
| Jeffrey S. Williams | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.